Global Generic Oncology Sterile Injectable Market Operational Updates in Industry Forecast 2025 Appraised By Global Players Eli Lilly & Company, Biocon Ltd., Baxter International Inc

Top Key Players:

Key companies covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

For In depth Information Get Sample Copy of this Report @ https://bit.ly/2IAi5nQ

Generic oncology sterile injectables are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectables have to adhere to regulations by the Food and Drug Administration (FDA) for the process of development of these injectables, which are equivalent to that for branded counterparts. These generic oncology sterile injectables are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus. These injectables are available at low prices, and therefore, are widely preferred over branded. Furthermore, R&D for generic drugs requires less capital, which increases competition to enter into generic oncology sterile injectable market as soon as the patent for branded injectables expires. However, the emergence of biosimilars has increased in past few years. After Europe, the number of biosimilars approved is increasing in the U.S. market. This is expected to contribute largely towards the generic oncology sterile injectable market growth during the forecast period.

The global generic oncology sterile injectable market was valued at US$ 8.9 Billion in 2016 and is expected to exhibit a CAGR of 11.4% over the forecast period (2017–2025).

Market Dynamics:

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancers were reported in the U.S. Manufacturers are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following U.S. Food and Drug administration approval in the U.S. market. Clofarabine is a generic version of Genzyme's Clolar, which is used for treatment of refractory acute lymphoblastic leukemia for patients aged 1 year to 21 years.

Expansion of manufacturing facilities and mergers between key players to develop strong pipeline product is expected to propel the generic oncology sterile injectable market growth:

Manufacturers in the market are focusing on collaboration and expansion of manufacturing facilities to tap into emerging markets. For instance, In July 2017, India-based Alembic Pharmaceuticals established an oncology manufacturing facility for injectables and lyophilized products in Gujarat. The manufacturing site has a capacity for 60 million tablets and capsules, approximately 20 million vials capacity for liquid injectables and lyophilized product. This new manufacturing facility will develop oncology injectables and lyophilized products for sales in international markets of the U.S., Middle East, North Africa, South Africa, and Australia. Furthermore, in December 2016 the global leader, Baxter International acquired India-based Claris Injectables for expanding its generic injectables product portfolio such as in oncology. This acquisition is expected to strengthen Baxter’s sales in hospitals in order to gain a leading position in generic injectables market. Also, in August 2017, Hikma Pharmaceuticals increased its additional manufacturing capacity by 70 million units exclusively for oncology injectables, which brings up its total to 550 million units. Therefore, this expansion will help Hikma to maintain its position in the market.:

In October 2014, Sagent Pharmaceuticals, Inc., a leader in injectables, acquired Omega Laboratories Limited. This acquisition is expected to aid in creating a robust product portfolio in generic injectables and expand Sagent’s global presence. Omega has a strong pipeline consisting of 26 generic injectables, planned to be launched between 2014 and 2019 and this is expected to aid Sagent.
In October 2017, Eli Lilly & Company received intellectual property rights for the vitamin regimen for Alimta (pemetrexed for injection) by the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO). These rights are expected to aid Eli Lilly & Company for development of next generation medicines.

Browse Complete Report For More Information @ https://bit.ly/2Tk9ium

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.